Summary
SEPSIS is a life-threatening reaction to infection with 48.9 million cases and 11 million deaths worldwide, 700.000 of those in the EU yearly. In epidemic-like situations such as COVID-19, SEPSIS is prevalent in >60% of the admitted patients and all non-survivors had SEPSIS. SEPSIS patients require immediate antibiotic therapy to prevent disease progression and reduce mortality. Therefore, clinicians administer empirically broad-spectrum antibiotics, which save lives but also lead to inappropriate treatments in up to 40% of cases. To identify the best antibiotic and dosage for each patient, clinicians in Acute Care and ICUs need to run diagnostics to identify both the pathogen causing the infection but test several antibiotics to find the specifically treating the infection. Antibiotic susceptibility testing takes too long to be useful in SEPSIS cases. Resistell, a Deep-Tech SME, has a breakthrough AST technology delivers AST diagnostic results in less than 2h instead of the current 24-48h. Clinicians around the world using RAPID-SEP-AST will for the first time select personalised antibiotic therapies to SEPSIS patients in the same day, increasing the success rate of treatment and reducing hospitalisation time and costs. This EIC project will accelerate RAPID-SEP-AST industrialisation, finalise CE-IVD approval and support market-critical proof of efficiency in a multicentre performance evaluation study at KOLs. RAPID-SEP-AST will allow rapid Resistell scale-up first in Europe using its strong network of EU distributors and then globally through leading global distributors. Resistell’s is a Women-Led Company (Danuta Cichocka CEO) with a strong cross-functional team of engineers, microbiologists, data scientists and serial entrepreneurs, supported by experienced Board of Directors and Scientific Advisors.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/961141 |
| Start date: | 01-08-2020 |
| End date: | 31-07-2022 |
| Total budget - Public funding: | 3 570 625,00 Euro - 2 499 437,00 Euro |
Cordis data
Original description
SEPSIS is a life-threatening reaction to infection with 48.9 million cases and 11 million deaths worldwide, 700.000 of those in the EU yearly. In epidemic-like situations such as COVID-19, SEPSIS is prevalent in >60% of the admitted patients and all non-survivors had SEPSIS. SEPSIS patients require immediate antibiotic therapy to prevent disease progression and reduce mortality. Therefore, clinicians administer empirically broad-spectrum antibiotics, which save lives but also lead to inappropriate treatments in up to 40% of cases. To identify the best antibiotic and dosage for each patient, clinicians in Acute Care and ICUs need to run diagnostics to identify both the pathogen causing the infection but test several antibiotics to find the specifically treating the infection. Antibiotic susceptibility testing takes too long to be useful in SEPSIS cases. Resistell, a Deep-Tech SME, has a breakthrough AST technology delivers AST diagnostic results in less than 2h instead of the current 24-48h. Clinicians around the world using RAPID-SEP-AST will for the first time select personalised antibiotic therapies to SEPSIS patients in the same day, increasing the success rate of treatment and reducing hospitalisation time and costs. This EIC project will accelerate RAPID-SEP-AST industrialisation, finalise CE-IVD approval and support market-critical proof of efficiency in a multicentre performance evaluation study at KOLs. RAPID-SEP-AST will allow rapid Resistell scale-up first in Europe using its strong network of EU distributors and then globally through leading global distributors. Resistell’s is a Women-Led Company (Danuta Cichocka CEO) with a strong cross-functional team of engineers, microbiologists, data scientists and serial entrepreneurs, supported by experienced Board of Directors and Scientific Advisors.Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Search
